Alnylam Pharmaceuticals, Inc. Stock price

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
147.4 USD -1.25% Intraday chart for Alnylam Pharmaceuticals, Inc. -1.13% -22.99%
Sales 2024 * 1.84B Sales 2025 * 2.26B Capitalization 18.57B
Net income 2024 * -524M Net income 2025 * -245M EV / Sales 2024 * 9.92 x
Net cash position 2024 * 340M Net cash position 2025 * 563M EV / Sales 2025 * 7.96 x
P/E ratio 2024 *
-35.3 x
P/E ratio 2025 *
-84.3 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.3%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing MT
How long will this bullish phase last? Our Logo
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
North American Morning Briefing : Earnings Back in -2- DJ
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss MT
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating MT
More news
1 day-1.25%
1 week-1.13%
Current month-2.44%
1 month+0.28%
3 months-20.85%
6 months-18.00%
Current year-22.99%
More quotes
1 week
145.54
Extreme 145.54
151.47
1 month
145.54
Extreme 145.54
164.02
Current year
143.52
Extreme 143.52
199.38
1 year
143.52
Extreme 143.52
218.88
3 years
117.58
Extreme 117.58
242.97
5 years
65.81
Extreme 65.81
242.97
10 years
31.38
Extreme 31.38
242.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-09-18
Director of Finance/CFO 56 19-08-12
Compliance Officer - 22-09-20
Members of the board TitleAgeSince
Director/Board Member 71 15-12-17
Director/Board Member 72 22-08-21
Director/Board Member 68 19-01-09
More insiders
Date Price Change Volume
24-03-18 147.4 -1.25% 460,718
24-03-15 149.3 +0.50% 906,206
24-03-14 148.5 +0.07% 505,848
24-03-13 148.4 +1.21% 858,993
24-03-12 146.6 -1.64% 683,597

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
147.4 USD
Average target price
220.8 USD
Spread / Average Target
+49.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Alnylam Pharmaceuticals, Inc. - Nasdaq